Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05512299
Other study ID # CMUH111-REC3-014
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date August 1, 2022
Est. completion date July 31, 2024

Study information

Verified date August 2022
Source China Medical University Hospital
Contact Ming-Kuei Lu, MD, PhD
Phone 8864-22052121
Email d4297@mail.cmuh.org.tw
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Cerebellocerebral connection plays an important function in motor control. Nowadays it can be investigated with neuroimaging and physiological methods in humans. Cerebellar inhibition (CBI) is a phenomenon showing a physiological suppression of the motor evoked potential (MEP) evoked from the motor cortex (M1) by delivering a preceding transcranial magnetic stimulation (TMS) on the contralateral cerebellum. Despite the mediated pathway is supposed to be the cerebello-dentato-thalamo-cortical (CDTC) circuit, there is no conclusive evidence. In addition, the clinical significant of CBI remains unclear. Based on our previous studies, we found that the patients with advanced tremor show an impaired Bereitschaftspotential. The findings support a notion that the patients with tremor bear dysfunction of the CDTC circuit. Intriguingly, the pathogenesis of the parkinsonian tremor is highly associated with the CDTC circuit. The "dimmer-switch" model suggests that the basal ganglia-thalamo-cortical circuit dysfunction may initiate the resting tremor, and the following CDTC circuit dysfunction will lead to the large-amplitude resting and postural tremor in Parkinson's disease (PD). The intention tremor is usually found in the patients with cerebellar degeneration, which is also relevant to the CDTC circuit dysfunction. We expect that the clinical significance of CBI and the mediated pathway of CBI will be clarified by this study.


Description:

The patients with hereditary cerebellar degeneration usually present intention tremor. Whether the intention tremor and the other cerebellar signs are correlated with their CBI finding remains unclear. By measuring the excitability curve (or input-output curve) of the CBI, we will be able to clarify this issue. We will first examine the relationship between CBI and clinical manifestations, particularly the different tremor types. Any CBI change following the PTT intervention in the PD patients will provide an excellent opportunity to investigate the relevance of the basal ganglia-thalamo-cortical circuit with CBI. The DTI findings will provide additional support to our hypothesis. In the first part of the study, we will recruit twenty age-matched patients into the three groups: PD with pure resting tremor, PD with postural tremor and cerebellar degeneration with intention tremor. They will receive clinical assessments, deep phenotyping with eye tracking, tremor recording and gait analysis. Diffusion tensor imaging focusing on pallidothalamic and dentatothalamic tractography will be done. The excitability curve of CBI will be examined with five TMS intensity steps. We suppose that there will be a gradient correlation of the CBI with the three tremor groups and the two diffusion tensor imaging tracts. In the second part of the study, we will follow up the PD patients who receive the pallidothalamic tractotomy via magnetic resonance imaging-guided focus ultrasound (MRg-FUS). Twelve PD patients with pure resting tremor and twelve PD patients with postural tremor will be monitored for one year. The pallidothalamic tractotomy provides an excellent opportunity to verify our findings in the first part. We suppose that the CBI change will occur in the patients with postural tremor instead of those with pure resting tremor. In summary, we expect that the clinical significance of CBI and the mediated pathway of CBI will be clarified by this study.


Recruitment information / eligibility

Status Recruiting
Enrollment 84
Est. completion date July 31, 2024
Est. primary completion date July 31, 2023
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria: Patients meet the diagnosis of PD with resting/postural or cerebellar degeneration with intention tremor based on the established consensus criteria. Exclusion Criteria: 1. Patients with contraindication to TMS or MRI examination. 2. Impairment of cognition that leads unable to fully cooperate with the oral commands during examinations. 3. Functional III or above congestive heart failure, or cancer with distant metastasis.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Transcranial Magnetic Stimulation
The CBI is recorded with two different TMS coils. The figure-of-eight coil (2X90 mm) is used for the motor cortex stimulation and the double cone coil (2X126 mm) is used for the cerebellar stimulation. The target recording muscle is first dorsal interosseous (FDI). The TMS intensity used to induce an average MEP amplitude of 0.5 mV is also determined. CBI is measured by a paired TMS with an inter-stimulus interval of 6 ms. That is, the test TMS at M1 is delivered 6 ms following the conditional TMS at contralateral cerebellum.

Locations

Country Name City State
Taiwan Department of Neurology, China Medical University Hospital Taichung

Sponsors (2)

Lead Sponsor Collaborator
China Medical University Hospital Ministry of Science and Technology, Taiwan

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline cerebellar inhibition (CBI) input output curve The CBI is recorded with two different TMS coils. The figure-of-eight coil (2X90 mm) is used for the motor cortex stimulation and the double cone coil (2X126 mm) is used for the cerebellar stimulation. The target recording muscle is first dorsal interosseous (FDI). The TMS intensity used to induce an average MEP amplitude of 0.5 mV is also determined. CBI is measured by a paired TMS with an inter-stimulus interval of 6 ms. That is, the test TMS at M1 is delivered 6 ms following the conditional TMS at contralateral cerebellum.
There are five TMS intensities used for the conditional cerebellar stimulation: 80%, 90%, 100%, 110% and 120% inion active motor threshold. Ten trials are recorded for each TMS intensity with a pseudorandomized order. The interval between two cerebellum-M1 TMS pairs is 8-seconds with 25% variability (i.e. 6-10 s) to reduce the prediction bias.
baseline (before the MRgFUS), 1-day, 24-weeks and 48-weeks after the MRgFUS
Primary Change from baseline functional magnetic resonance imaging In this study we mainly adopt diffusion tensor imaging (DTI) to quantify two interested projections: the pallidothalamic pathway and the dentatothalamic pathway.
Diffusion tensor imaging of fifty gradient directions is acquired with five non-gradient (B0) images. The B-value is 1500 s/mm2, FOV = 240mm x 240mm, image matrix = 96 x 96, slice thickness = 2.5mm with zero gap. The voxel size is 2.5 x 2.5 x 2.5 mm3 isotopically. The TR was approximately 10000ms which is adjusted to match the slice number of requirements. Image acquired with axial direction, 56 slices to cover the whole brain.
baseline (before the MRgFUS), 48-weeks after the MRgFUS
Secondary Change from baseline clinical evaluations In addition to a detailed history and neurological examinations, the clinical assessment also includes International Parkinson and Movement Disorder Society-sponsored UPDRS (MDS-UPDRS) and clinical rating scale for tremor (CRST)for the PD patients. The Scale for the Assessment and Rating of Ataxia (SARA) and CRST are adopted for the patients with cerebellar degeneration. baseline (before the MRgFUS), 1-day, 24-weeks and 48-weeks after the MRgFUS
Secondary Change from baseline gait analysis The gait analysis system (Zeno Walkway System with PKMAS) provides detailed gait parameters including velocity, cadence, pressure and cyclogram.
Variables in gait analysis: 1.Gait initiation, 2.Level walking, 3.Gait termination.
baseline (before the MRgFUS), 1-day, 24-weeks and 48-weeks after the MRgFUS
Secondary Change from baseline surface electromyography and eye-tracking pattern The pattern of eye-tracking and surface electromyography (SEMG) with accelerometer will be recorded to monitor the therapy outcome. The eye-tracking system (EyeLink 1000 Plus) will track eye movements regarding the target fixation, saccade, smooth pursuit and image stimuli. The multiple SEMG recording (CED Power1401) will focus on the arm and hand muscles relevant to the tremor (e.g. first dorsal interosseous, abductor pollicis brevis, extensor carpi radialis and flexor carpi radialis). The accelerometer can also reveal the mechanical information of the tremor oscillation. baseline (before the MRgFUS), 1-day, 24-weeks and 48-weeks after the MRgFUS
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02427646 - Kinematic-guided BoNT-A Treatment for ET and PD Tremor Phase 2
Completed NCT01018485 - The Efficacy of Botulinum Toxin in Disabling Multiple Sclerosis (MS) Tremor Phase 3
Completed NCT02087046 - Deep Brain Stimulation (DBS) for the Suppression of Tremor N/A
Recruiting NCT05413291 - Natural History Protocol for Movement Disorders
Recruiting NCT04654429 - Does Higher OT Temperature and IV Ondansetron Reduce Incidence of PSS in Parturients? Phase 4
Recruiting NCT04825119 - Hyperkinetic Movements in Patients With Disease of Motor Neurons and Their Response to Treatment With Nusinersen
Recruiting NCT05150106 - Characterization of Clinical Phenotypes of Laryngeal Dystonia and Voice Tremor
Completed NCT05152836 - The Effect of Vibrotactile Stimulation on Parkinson's Tremor N/A
Recruiting NCT04071847 - Abbott DBS Post-Market Study of Outcomes for Indications Over Time
Completed NCT02046863 - Pilot Study for Automated Deep Brain Stimulation Programming N/A
Not yet recruiting NCT06378619 - Tapping Test and the Archimedean Spiral for the Differential Diagnosis of Tremor. Machine Learning Approach
Completed NCT03300193 - The Effect of Lesion Characteristics in MRgFUS on Tremor in Essential Tremor and Parkinson's Disease N/A
Completed NCT01932463 - ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) for Treatment of Tremor N/A
Recruiting NCT05216770 - Understanding Disorder-specific Neural Pathophysiology in Laryngeal Dystonia and Voice Tremor Early Phase 1
Not yet recruiting NCT06174948 - The Use of the CUE1 in People With Parkinson's Disease and Related Disorders N/A
Completed NCT01093027 - Electrophysiological Study of the Effects of Limb Cooling on Essential Tremor N/A
Completed NCT00001667 - Genotype/Phenotype Correlation of Movement Disorders and Other Neurological Diseases N/A
Completed NCT00001324 - PET Scan to Study Brain Control of Human Movement
Completed NCT04299087 - Repetitive Transcranial Magnetic Stimulation (rTMS) for Dystonia and Tremor N/A
Recruiting NCT05150093 - Deep Brain Stimulation in Laryngeal Dystonia and Voice Tremor N/A